Diagonal's $125M PIPE Bets on Agonist Antibody Platform

Diagonal Therapeutics has secured $125 million in a private investment in public equity (PIPE) financing to propel its lead bispecific antibody agonist, DGN-001, into mid-stage testing. The company is pioneering a platform to discover and develop agonist antibodies that activate receptor complexes, a historically challenging drug class. Its lead asset, DGN-001, is designed to selectively activate the ALK1 receptor complex to restore signaling in diseases like hereditary hemorrhagic telangiectasia (HHT), with Phase 1 data expected in 2026. The new capital is earmarked specifically to fund a Phase 2 trial for DGN-001 in HHT and to advance a second, undisclosed bispecific agonist candidate toward clinical development. While the investor syndicate was not disclosed, the sizable PIPE follows Diagonal's $128 million Series A in 2024 and suggests continued institutional backing for its platform. The deal underscores investor appetite for novel antibody engineering approaches that move beyond simple receptor blockade.